title: Revascularization, stenting, and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock.
abstract: Randomized clinical trials have demonstrated a reduction in mortality with early revascularization of patients with acute myocardial infarction (AMI) complicated by cardiogenic shock, and recent single-center studies have particularly suggested further benefit for coronary stenting. The purpose of this study was to examine the use of revascularization and coronary stenting for patients with shock from a multicenter, international perspective. Patients with AMI complicated by cardiogenic shock (n = 583) who enrolled between April 1999 and June 2001 were prospectively identified from the large, multinational, observational Global Registry of Acute Coronary Events. We examined the use of coronary reperfusion strategies, adjunctive therapy, and hospital mortality in this group of patients. Cardiac catheterization (52%) and revascularization (43%) were performed in approximately half of the cardiogenic shock patients. Elderly patients (age >/=75 years) comprised 40% of the shock cohort. Regional differences were seen in the use of revascularization, adjunctive medical therapy, and type of revascularization used (coronary stenting). Total hospital mortality was 59%, but case fatality rates ranged from 35% for patients who underwent coronary stenting to 74% for patients who did not undergo any cardiac catheterization. Percutaneous coronary intervention with coronary stenting was the most powerful predictor of hospital survival (odds ratio 3.99, 95% confidence interval 2.41 to 6.62). Thus, cardiogenic shock continues to be a devastating complication of AMI, and relative underuse of a revascularization strategy may be related to the large proportion of elderly patients in this population. In this multinational registry study, coronary stenting was the most powerful independent predictor of hospital survival.
authors.affiliation: University of Vermont College of Medicine, Fletcher Allen Health Care, Burlington, Vermont 05401, USA. harold.dauerman@vtmednet.org
authors.forename: Harold L
authors.initials: HL
authors.lastname: Dauerman
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Goldberg
authors.forename: Kami
authors.initials: K
authors.lastname: White
authors.forename: Joel M
authors.initials: JM
authors.lastname: Gore
authors.forename: Immad
authors.initials: I
authors.lastname: Sadiq
authors.forename: Enrique
authors.initials: E
authors.lastname: Gurfinkel
authors.forename: Andrzej
authors.initials: A
authors.lastname: Budaj
authors.forename: Esteban
authors.initials: E
authors.lastname: Lopez de Sa
authors.forename: Jose
authors.initials: J
authors.lastname: Lopez-Sendon
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015331:Cohort Studies; D005260:Female; D017052:Hospital Mortality; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000401:mortality / Q000628:therapy*; D009204:Myocardial Revascularization; D010043:Outcome and Process Assessment, Health Care; D011446:Prospective Studies; D012042:Registries; D012770:Shock, Cardiogenic / Q000401:mortality / Q000628:therapy*; D015607:Stents; D015996:Survival Rate